Grant: Alliance Grants
McMaster University
$171,333.00
Design and evaluation of the physical-chemical -material properties parameters: Strategically expanding a prodrug platform for controlled drug delivery
FY 2021-22
Summary
The development of new strategies to improve drug delivery has the potential to significantly improve patient outcomes. Ripple Therapeutics has developed a new approach to developing implants based on a discovery that prodrugs (an inactive version of a drug) can be processed into an implant without the use of a polymer to hold the implant together and control the release rate of the drug. This reduces the amount of drug needed to treat patients by more efficiently controlling how the drug is released from the implant, and prevents exposure of the patient to foreign polymers. In this grant, the discovery that Ripple Therapeutics has made with a class of drugs called corticosteroids will be expanded to other drug classes that would benefit from controlled delivery. An engineering approach will be used to prepare implants made solely of prodrugs using drugs that are standard of care for glaucoma treatment and opioid abuse disorder. The use of prodrugs as a carrier system for controlling the release of other drugs will also be evaluated. The material characteristics of these implants will be assessed. Studies will be performed to determine if these implants can predictably control drug release and prototypes will be prepared and characterized. Safety of the implant materials will also be confirmed. The successful completion of this project will accelerate the development of new treatment options for patients in Canada and internationally, improving quality of life and saving lives.
Program
Alliance Grants
Recipient
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data
As published
Application id
556570-2020
Name nom
Sheardown, Heather
Department département
Chemical Engineering
Organization id
27
Institution établissement
McMaster University
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2021
Competition year année de concours
2020
Award amount
171333
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1208
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Materials sciences
Area of application fr
Sciences des matériaux
Research subject code
1902
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical materials
Research subject fr
Matériaux biomédicaux
Installment
inst:2
Partie
1
Nb partie
2
Application title
Design and evaluation of the physical-chemical -material properties parameters: Strategically expanding a prodrug platform for controlled drug delivery
Keyword
NSERC
Application summary
The development of new strategies to improve drug delivery has the potential to significantly improve patient outcomes. Ripple Therapeutics has developed a new approach to developing implants based on a discovery that prodrugs (an inactive version of a drug) can be processed into an implant without the use of a polymer to hold the implant together and control the release rate of the drug. This reduces the amount of drug needed to treat patients by more efficiently controlling how the drug is released from the implant, and prevents exposure of the patient to foreign polymers. In this grant, the discovery that Ripple Therapeutics has made with a class of drugs called corticosteroids will be expanded to other drug classes that would benefit from controlled delivery. An engineering approach will be used to prepare implants made solely of prodrugs using drugs that are standard of care for glaucoma treatment and opioid abuse disorder. The use of prodrugs as a carrier system for controlling the release of other drugs will also be evaluated. The material characteristics of these implants will be assessed. Studies will be performed to determine if these implants can predictably control drug release and prototypes will be prepared and characterized. Safety of the implant materials will also be confirmed. The successful completion of this project will accelerate the development of new treatment options for patients in Canada and internationally, improving quality of life and saving lives.